GeneGo Extends Agreement with Merck & Co.
News Jun 04, 2008
GeneGo, Inc. has announced that Merck & Co., Inc. has extended its global enterprise agreement. This agreement provides Merck with access to GeneGo's content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo's internal database of disease biomarkers.
"Effective use of powerful systems biology data mining & analysis solutions have become an essential component of modern day drug discovery and development," said Julie Bryant, VP business development.
"Merck is one of our first customers and we are pleased that they have chosen to renew and extend their agreement."
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.